ERBB2 and breast cancer: In addition, a significantly higher proportion of patients in subtype 1 were diagnosed with hormone receptor positive (HR +) BC, while patients in subtype 2 and subtype 3 were more likely to be TNBC and Her-2 +, respectively (Table 1).